NEW YORK ( TheStreet) -- Shares of Cell Therapeutics (Nasdaq: CTIC) were gapping down Friday morning with an open price 10.7% lower than Thursday's closing price. The stock closed at 28 cents Thursday and opened today's trading at 25 cents. The average volume for Cell has been 4.1 million shares per day over the past 30 days. Cell has a market cap of $245 million and is part of the health care sector and drugs industry. Shares are down 23.3% year to date as of the close of trading on Thursday. Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for the treatment of cancer. TheStreet Ratings rates Cell as sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and poor profit margins. You can view the full Cell Ratings Report. Get more investment ideas from our investment research center.
More from Markets
Trump Says U.S. and China Reach Preliminary Trade Accord
The president cited progress in the 18-month trade war on topics including currency, intellectual property and financial services. And China will buy more U.S. agricultural products. The U.S. for its part will delay the tariff increase that was due next week.
Stocks End Higher; Trump Announces 'Substantial Phase One' Trade Deal
Stocks finish sharply higher Friday on signs the U.S. and China have taken steps to ease trade tensions between the two countries.
Amazon Earnings May Not Impress, But Here's Why the Stock Could Still Be a Buy
Amazon Web Services remains a huge bright spot for the stock, analysts say.